Superscan in First Posttherapeutic 177 Lu-PSMA Scan.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 39629689.
- Also identified by DOI 10.1097/RLU.0000000000005624.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This case highlights the effectiveness of 177 Lu-PSMA therapy in a 70-year-old man with castration-resistant prostate cancer who has extensive skeletal metastases in posttherapeutic whole-body imaging. A 70-year-old man with extensive skeletal metastases underwent 4 cycles of 177 Lu-PSMA-617 therapy. A whole-body 177 Lu-PSMA scan after the first cycle showed diffuse skeletal lesions, with minimal PSMA uptake in the kidneys and salivary glands. A whole-body scan after the fourth cycle of 177 Lu-PSMA showed a complete response of skeletal metastases with normal PSMA uptake in the kidneys and salivary glands. According to RECİP 1.0, the patient was considered a complete response.
Medical subject headings
- Lutetium
- Dipeptides
- Heterocyclic Compounds, 1-Ring
- Radioisotopes